NRX Pharmaceuticals, Inc. - NRXP STOCK NEWS

NRx Pharmaceuticals (Nasdaq: NRXP) announced the appointment of Seth Van Voorhees, Ph.D., as Chief Financial Officer and Treasurer, effective June 13, 2022. His extensive experience in corporate finance and investment banking aims to enhance the company's focus on its psychiatry franchise, particularly the development of NRX-101, a therapy for severe bipolar depression. The company is advancing clinical trials, including a Phase II trial for bipolar patients with acute suicidal ideation. Interim CEO Robert Besthof thanked former CFO Ira Strassberg for his contributions to internal controls and finance functions.

NRx Pharmaceuticals (Nasdaq: NRXP) announced that the Data Safety and Monitoring Board (DSMB) has recommended halting the ACTIV-3b (TESICO) study evaluating ZYESAMI® (aviptadil) for Critical COVID-19 patients due to futility. Approximately 75% of the 640 patients were reviewed, showing no significant difference in the primary or secondary endpoints compared to placebo. Despite the cessation, no safety concerns were raised, and known side effects were managed. NRx will continue exploring ZYESAMI's potential in other respiratory disorders while focusing on its NRX-101 drug for bipolar depression.

NRx Pharmaceuticals (Nasdaq: NRXP) will provide a corporate update during a webcast on May 24, 2022, at 7:00 a.m. ET, led by interim CEO Robert Besthof and other executives. The presentation will be part of the hybrid H.C. Wainwright & Co. Global Investment Conference. Following the event, a replay will be available on NRx's website for 30 days. The company is known for NRX-101, which targets severe bipolar depression, and ZYESAMI®, currently in a Phase III trial for COVID-19 patients.

NRx Pharmaceuticals (Nasdaq: NRXP) reported its Q1 2022 financial results, highlighting advances in key compounds NRX-101 and ZYESAMI®. The Phase II study of NRX-101 for bipolar depression has commenced, with patient enrollment beginning May 12, 2022. The company has also submitted a new Emergency Use Authorization request for ZYESAMI® to treat Critical COVID-19 patients. Financially, the net loss was $13.4 million, down from $25.5 million a year prior, indicating improvement. Cash reserves increased to $40.2 million, sufficient to support operations for at least 12 months.

NRx Pharmaceuticals has enrolled its first patient in a psychiatry study focusing on bipolar depression with sub-acute suicidality. This trial is part of the development of NRX-101, a patented combination of D-cycloserine and lurasidone, both approved and non-abusive drugs. Notably, 50% of individuals with bipolar disorder experience suicidal ideation or attempts. A Phase IIb/III registrational trial for acute suicidal ideation in bipolar patients is planned for later this year, leveraging Breakthrough Therapy Designation from the FDA based on positive prior data.

NRx Pharmaceuticals, a clinical-stage biopharmaceutical company, will report its first quarter 2022 financial results on May 16, 2022, before the market opens. The company will host a conference call at 8:30 AM ET to discuss these results along with clinical and corporate updates. Investors can participate by submitting questions via email by 4:00 PM ET on May 13, 2022. The company is advancing treatments for COVID-19 and severe bipolar depression, with investigational products ZYESAMI® and NRX-101 receiving FDA designations.

NRx Pharmaceuticals has submitted a new Breakthrough Therapy designation request to the FDA for ZYESAMI® (aviptadil) targeting patients with Critical COVID-19 who were also treated with remdesivir. The submission includes safety data from about 750 patients and demonstrates a four-fold increase in survival odds compared to placebo at 60 days. This request follows the FDA's earlier feedback for additional clinical evidence regarding aviptadil's efficacy. The company emphasizes that there are no new adverse drug reactions reported, reinforcing ZYESAMI®'s safety profile in critical care settings.

NRx Pharmaceuticals (Nasdaq: NRXP) will present a corporate update at the 21st Annual Needham Virtual Healthcare Conference on April 14, 2022, at 4:30 PM ET. Interim CEO Robert Besthof and other executives will provide insights on the company's progress and future plans. The presentation will be accessible to investors, media, and the public via a live webcast. NRx specializes in biopharmaceuticals, with its lead products in Phase III trials, including ZYESAMI®, targeted for COVID-19, and NRX-101 for severe bipolar depression.

NRx Pharmaceuticals (Nasdaq: NRXP) reported its financial results for the year ended December 31, 2021, showing a net loss of $93.1 million, or $1.98 per share. Research and development expenses increased significantly to $20.3 million, primarily due to clinical trials for ZYESAMI®. General and administrative expenses skyrocketed to $74.9 million, largely driven by non-cash stock-based compensation. Despite these losses, NRx has sufficient cash of $27.6 million to support operations for the next 12 months and is focused on two Phase III assets: ZYESAMI® for Critical COVID-19 and NRX-101 for bipolar depression.